Financhill
Buy
59

IGC Quote, Financials, Valuation and Earnings

Last price:
$0.33
Seasonality move :
-1.56%
Day range:
$0.32 - $0.34
52-week range:
$0.25 - $0.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.26x
P/B ratio:
4.17x
Volume:
105.2K
Avg. volume:
209.2K
1-year change:
-33.08%
Market cap:
$26.1M
Revenue:
$1.3M
EPS (TTM):
-$0.11

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
IGC
IGC Pharma
$305K -$0.02 3.39% -50% $3.88
CVM
CEL-SCI
-- -- -- -- $8.00
LCTX
Lineage Cell Therapeutics
$1.7M -$0.03 4.59% -- $3.92
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$21.6M -- -14.21% -- $14.00
TOVX
Theriva Biologics
-- -$1.56 -- -95.63% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
IGC
IGC Pharma
$0.33 $3.88 $26.1M -- $0.00 0% 19.26x
CVM
CEL-SCI
$2.51 $8.00 $7.6M -- $0.00 0% --
LCTX
Lineage Cell Therapeutics
$0.68 $3.92 $155.9M -- $0.00 0% 15.08x
NBY
NovaBay Pharmaceuticals
$0.57 $0.85 $3.3M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$1.56 $14.00 $124.2M 39.00x $0.00 0% 2.19x
TOVX
Theriva Biologics
$0.43 $7.00 $3.5M -- $0.00 0% 0.33x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
IGC
IGC Pharma
2.1% -0.278 0.51% 0.21x
CVM
CEL-SCI
-- 1.145 -- --
LCTX
Lineage Cell Therapeutics
-- 0.143 -- 3.68x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- 1.057 -- 1.62x
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
LCTX
Lineage Cell Therapeutics
$1.5M -$6.5M -22.68% -22.68% -433.09% -$5M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M
TOVX
Theriva Biologics
-- -$4.4M -- -- -- -$4.8M

IGC Pharma vs. Competitors

  • Which has Higher Returns IGC or CVM?

    CEL-SCI has a net margin of -711.67% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -116.24% beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About IGC or CVM?

    IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9462.71%. Given that CEL-SCI has higher upside potential than IGC Pharma, analysts believe CEL-SCI is more attractive than IGC Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGC
    IGC Pharma
    2 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is IGC or CVM More Risky?

    IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.498, suggesting its less volatile than the S&P 500 by 50.196%.

  • Which is a Better Dividend Stock IGC or CVM?

    IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGC or CVM?

    IGC Pharma quarterly revenues are $257K, which are larger than CEL-SCI quarterly revenues of --. IGC Pharma's net income of -$1.8M is higher than CEL-SCI's net income of -$6.6M. Notably, IGC Pharma's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGC
    IGC Pharma
    19.26x -- $257K -$1.8M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns IGC or LCTX?

    Lineage Cell Therapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -275.57%. IGC Pharma's return on equity of -116.24% beat Lineage Cell Therapeutics's return on equity of -22.68%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
    LCTX
    Lineage Cell Therapeutics
    97.6% -$0.02 $77.7M
  • What do Analysts Say About IGC or LCTX?

    IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Lineage Cell Therapeutics has an analysts' consensus of $3.92 which suggests that it could grow by 473.54%. Given that IGC Pharma has higher upside potential than Lineage Cell Therapeutics, analysts believe IGC Pharma is more attractive than Lineage Cell Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGC
    IGC Pharma
    2 0 0
    LCTX
    Lineage Cell Therapeutics
    4 1 0
  • Is IGC or LCTX More Risky?

    IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Lineage Cell Therapeutics has a beta of 1.414, suggesting its more volatile than the S&P 500 by 41.436%.

  • Which is a Better Dividend Stock IGC or LCTX?

    IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lineage Cell Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Lineage Cell Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGC or LCTX?

    IGC Pharma quarterly revenues are $257K, which are smaller than Lineage Cell Therapeutics quarterly revenues of $1.5M. IGC Pharma's net income of -$1.8M is higher than Lineage Cell Therapeutics's net income of -$4.1M. Notably, IGC Pharma's price-to-earnings ratio is -- while Lineage Cell Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 15.08x for Lineage Cell Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGC
    IGC Pharma
    19.26x -- $257K -$1.8M
    LCTX
    Lineage Cell Therapeutics
    15.08x -- $1.5M -$4.1M
  • Which has Higher Returns IGC or NBY?

    NovaBay Pharmaceuticals has a net margin of -711.67% compared to IGC Pharma's net margin of -49.65%. IGC Pharma's return on equity of -116.24% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About IGC or NBY?

    IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 50.23%. Given that IGC Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe IGC Pharma is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGC
    IGC Pharma
    2 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is IGC or NBY More Risky?

    IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock IGC or NBY?

    IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGC or NBY?

    IGC Pharma quarterly revenues are $257K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. IGC Pharma's net income of -$1.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, IGC Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGC
    IGC Pharma
    19.26x -- $257K -$1.8M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns IGC or PLX?

    Protalix BioTherapeutics has a net margin of -711.67% compared to IGC Pharma's net margin of -35.79%. IGC Pharma's return on equity of -116.24% beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About IGC or PLX?

    IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 797.44%. Given that IGC Pharma has higher upside potential than Protalix BioTherapeutics, analysts believe IGC Pharma is more attractive than Protalix BioTherapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGC
    IGC Pharma
    2 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is IGC or PLX More Risky?

    IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.048, suggesting its less volatile than the S&P 500 by 104.824%.

  • Which is a Better Dividend Stock IGC or PLX?

    IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGC or PLX?

    IGC Pharma quarterly revenues are $257K, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. IGC Pharma's net income of -$1.8M is higher than Protalix BioTherapeutics's net income of -$3.6M. Notably, IGC Pharma's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 39.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 2.19x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGC
    IGC Pharma
    19.26x -- $257K -$1.8M
    PLX
    Protalix BioTherapeutics
    2.19x 39.00x $10.1M -$3.6M
  • Which has Higher Returns IGC or TOVX?

    Theriva Biologics has a net margin of -711.67% compared to IGC Pharma's net margin of --. IGC Pharma's return on equity of -116.24% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
    TOVX
    Theriva Biologics
    -- -$1.55 --
  • What do Analysts Say About IGC or TOVX?

    IGC Pharma has a consensus price target of $3.88, signalling upside risk potential of 1083.21%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1527.91%. Given that Theriva Biologics has higher upside potential than IGC Pharma, analysts believe Theriva Biologics is more attractive than IGC Pharma.

    Company Buy Ratings Hold Ratings Sell Ratings
    IGC
    IGC Pharma
    2 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is IGC or TOVX More Risky?

    IGC Pharma has a beta of 1.503, which suggesting that the stock is 50.252% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock IGC or TOVX?

    IGC Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios IGC or TOVX?

    IGC Pharma quarterly revenues are $257K, which are larger than Theriva Biologics quarterly revenues of --. IGC Pharma's net income of -$1.8M is higher than Theriva Biologics's net income of -$4.3M. Notably, IGC Pharma's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma is 19.26x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    IGC
    IGC Pharma
    19.26x -- $257K -$1.8M
    TOVX
    Theriva Biologics
    0.33x -- -- -$4.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is up 454.46% over the past day.

Buy
58
TNXP alert for May 28

Tonix Pharmaceuticals Holding [TNXP] is up 27.51% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is up 19.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock